Mabwell Overview

  • Founded
  • 2017
  • Status
  • Private
  • Latest Deal Type
  • Series A
  • Latest Deal Amount
  • $278M
Latest Deal Amount
  • Investors
  • 12

Mabwell General Information


Developer of biopharmaceutical technology focused on oncology, autoimmunity, anti-infection and ophthalmic diseases. The company has a high-throughput antibody drug discovery platform, a complete pharmaceutical research system, and mature process development capabilities and is committed to the research and development and manufacturing of macromolecular innovative drugs such as therapeutic monoclonal antibodies and long-acting recombinant proteins.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Industries
Drug Discovery
Primary Office
  • Floor 4, Building 3, No. 576 Li Bing Road (Creation Park)
  • Pudong New District
  • Shanghai, 201210
  • China
+86 021 0000 0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Mabwell Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC (Series A) 29-Apr-2020 $278M 00000 00.000 Completed Generating Revenue
To view Mabwell’s complete valuation and funding history, request access »

Mabwell Executive Team (1)

Name Title Board Seat Contact Info
Datao Liu Ph.D Founder & President
To view Mabwell’s complete executive team members history, request access »

Mabwell Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Founder H Fund Corporate Venture Capital Minority 000 0000 000000 0
Ganzhou Development Investment Other Minority 000 0000 000000 0
Haitong Leading Capital Management Venture Capital Minority 000 0000 000000 0
Jiangsu Winfast Investment Asset Manager Minority 000 0000 000000 0
Loyal Valley Capital Growth/Expansion Minority 000 0000 000000 0
You’re viewing 5 of 12 investors. Get the full list »